Thursday April 13, 2023
Audited results for year ended 31 December 2022
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Audited results for the year ended 31 December 2022 Exclusive North American partnering deal worth up to $570m plus royalties secured for […]
Tuesday April 4, 2023
Landmark data published on NTCD-M3
Destiny Pharma plc(“Destiny Pharma” or “the Company”) Landmark data published on successful NTCD‐M3gut colonisation after fidaxomicin administration Brighton, United Kingdom ‐ 4 April 2023 ‐ Destiny Pharma (AIM: DEST), a clinical stage innovative […]
Monday April 3, 2023
Notice of Results and Investor Presentation
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Investor Presentation Brighton, United Kingdom – 3 April 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage […]
Friday March 24, 2023
Landmark XF-73 Phase 2 data published in US journal
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of […]
Thursday March 16, 2023
Agreement with Sebela Pharmaceuticals for NTCD-M3
Destiny Pharma PLC Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization […]
Thursday March 16, 2023